47 ud af 47 tidsskrifter valgt, søgeord (hepatitis B, hepatitis C, HBV, HCV, direct acting agent, stikuheld) valgt, emner højest 30 dage gamle, sorteret efter nyeste først.
31 emner vises.
1
Autophagy‐related protein 5 (ATG5) interacts with bone marrow stromal cell antigen 2 (BST2) to stimulate HBV replication through antagonizing the antiviral activity of BST2
Qingyuan Li, Wenxian Wen, Yijin Wang, Tao Gong, Xinwei Wang, Qi Tan, Bin Fan, He Xie, Yujia Li, Shilin Li, Chunhui Yang, Zhonghui Zhou, Xiaoqiong Duan, Wenyu Lin, Limin Chen
Journal of Medical Virology, 16.05.2024
Tilføjet 16.05.2024
2
Four weeks of off‐treatment follow‐up is sufficient to determine virologic responses at off‐treatment week 12 in patients with hepatitis C virus infection receiving fixed‐dose pangenotypic direct‐acting antivirals
Chen‐Hua Liu, Yu‐Ping Chang, Ji‐Yuh Lee, Chi‐Yi Chen, Wei‐Yu Kao, Chih‐Lin Lin, Sheng‐Shun Yang, Yu‐Lueng Shih, Cheng‐Yuan Peng, Fu‐Jen Lee, Ming‐Chang Tsai, Shang‐Chin Huang, Tung‐Hung Su, Tai‐Chung Tseng, Chun‐Jen Liu, Pei‐Jer Chen, Jia‐Horng Kao
Journal of Medical Virology, 16.05.2024
Tilføjet 16.05.2024
3
Associations of CD4 cell count measures with infection-related and infection-unrelated cancer risk among people with HIV
Nicolau, Ioana A.; Moineddin, Rahim; Brooks, Jennifer D.; Antoniou, Tony; Gillis, Jennifer L.; Kendall, Claire E.; Cooper, Curtis; Cotterchio, Michelle; Salters, Kate; Smieja, Marek; Kroch, Abigail E.; Price, Colleen; Mohamed, Anthony; Burchell, Ann N.
Journal of Acquired Immune Deficiency Syndromes, 16.05.2024
Tilføjet 16.05.2024
Background: People with human immunodeficiency virus (HIV) are at higher risk of infection-related cancers than the general population which could be due, in part, to immune dysfunction. Our objective was to examine associations between four CD4 count measures as indicators of immune function and infection-related and -unrelated cancer risk. Setting: We conducted a cohort study of adults with HIV who were diagnosed with cancer in Ontario, Canada. Incident cancers were identified from January 1, 1997 to December 31, 2020. Methods: We estimated adjusted hazard ratios (aHR) for the associations between CD4 measures (baseline CD4, nadir CD4, time-updated CD4, time-updated CD4:CD8) and cancer incidence rates using competing risk analyses, adjusted for socio-demographic factors, history of hepatitis B or C infection, baseline viral load, smoking, and alcohol use. Results: Among 4,771 people with HIV, contributing 59,111 person-years of observation, a total of 549 cancers were observed. Low baseline CD4 (
Læs mere
Tjek på PubMed
4
Development of a dual channel detection system for pan-genotypic simultaneous quantification of hepatitis B and delta viruses
Yongzhen LiuStephanie MayaSebastian CarverAoife K. O’ConnellAnna E. TsengHans P. GertjeKathleen SenecaRonald G. NahassNicholas A. CrosslandAlexander Plossa Department of Molecular Biology, Princeton University, Princeton, NJ, USAb National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USAc Infectious Disease Care, Hillsborough, NJ, USAd Department of Pathology and Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USAe Department of Virology, Immunology, & Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA
Emerg Microbes Infect, 14.05.2024
Tilføjet 14.05.2024
5
A potential antiviral role for CCR5+CD8+ T cells in children with hepatitis B
Aoxue Tan, Yi He, Yingzhi Zhou, Xiaorong Peng, Yunan Chang, Mingli Peng, Hong Ren, Hongmei Xu
Journal of Medical Virology, 14.05.2024
Tilføjet 14.05.2024
6
The clinical significance of long non-coding RNAs MALAT1 and CASC2 in the diagnosis of HCV-related hepatocellular carcinoma
Rehab M. Golam, Mahmoud A. F. Khalil, Olfat G. Shaker, Tarek I. Ahmed, Mohamed K. Abd Elguaad, Essam A. Hassan, Mahmoud R. M. El-Ansary, Ahmed Ismail, Yasser I. Kandil, Osama A. Mohammed, Ahmed S. Doghish
PLoS One Infectious Diseases, 13.05.2024
Tilføjet 13.05.2024
by Rehab M. Golam, Mahmoud A. F. Khalil, Olfat G. Shaker, Tarek I. Ahmed, Mohamed K. Abd Elguaad, Essam A. Hassan, Mahmoud R. M. El-Ansary, Ahmed Ismail, Yasser I. Kandil, Osama A. Mohammed, Ahmed S. Doghish Background Globally, hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death due to a lack of early predictive and/or diagnostic tools. Thus, research for a new biomarker is important. LncRNAs play a functional role in target gene regulation and their deregulation is associated with several pathological conditions including HCC. Objective This study aimed to explore the diagnostic potential of two LncRNAs MALAT1 and CASC2 in HCC compared to the routinely used diagnostic biomarker. Materials and methods The current study is a case-control study carried out at Fayoum University Hospital and conducted on 89 individuals. The study included three groups of 36 HCC patients on top of HCV(HCC/HCV), 33 HCV patients, and 20 healthy volunteers as a control group. All study subjects were subjected to radiological examinations. The determination of CBC was performed by the automated counter and liver function tests by the enzymatic method were performed. In addition, HCV RNA quantification and the expression level of two LncRNAs (MALAT1 and CASC2) were performed by qRT-PCR. Results The results revealed a statistically significant difference between study groups regarding liver function tests with a higher mean in HCC/HCV group. Also, serum MALAT1 significantly up-regulated in HCV (11.2±2.8) and HCC/HCV (4.56±1.4) compared to the control group. Besides, serum CASC2 levels in the HCV group were significantly upregulated (14.9±3.6), while, downregulated in the HCC group (0.16± 0.03). Furthermore, The ROC analysis for diagnostic efficacy parameters indicated that CASC2 has higher accuracy (94.6%) and sensitivity (97.2%) for HCC diagnosis than AFP with an accuracy of (90.9%), sensitivity (69.4%), and MALAT1 showed an accuracy of (56.9%), sensitivity (72.2%). Conclusion Our study results indicated that CASC2 is a promising biomarker and is considered better and could help in HCC diagnosis on top of HCV than MALAT1 and the routine biomarker AFP.
Læs mere
Tjek på PubMed
7
Immortalized hepatocyte-like cells: A competent hepatocyte model for studying clinical HCV isolate infection
Yongyut Pewkliang, Piyanoot Thongsri, Phichaya Suthivanich, Nipa Thongbaiphet, Jiraporn Keatkla, Ekawat Pasomsub, Usanarat Anurathapan, Suparerk Borwornpinyo, Adisak Wongkajornsilp, Suradej Hongeng, Khanit Sa-ngiamsuntorn
PLoS One Infectious Diseases, 13.05.2024
Tilføjet 13.05.2024
by Yongyut Pewkliang, Piyanoot Thongsri, Phichaya Suthivanich, Nipa Thongbaiphet, Jiraporn Keatkla, Ekawat Pasomsub, Usanarat Anurathapan, Suparerk Borwornpinyo, Adisak Wongkajornsilp, Suradej Hongeng, Khanit Sa-ngiamsuntorn More than 58 million individuals worldwide are inflicted with chronic HCV. The disease carries a high risk of end stage liver disease, i.e., cirrhosis and hepatocellular carcinoma. Although direct-acting antiviral agents (DAAs) have revolutionized therapy, the emergence of drug-resistant strains has become a growing concern. Conventional cellular models, Huh7 and its derivatives were very permissive to only HCVcc (JFH-1), but not HCV clinical isolates. The lack of suitable host cells had hindered comprehensive research on patient-derived HCV. Here, we established a novel hepatocyte model for HCV culture to host clinically pan-genotype HCV strains. The immortalized hepatocyte-like cell line (imHC) derived from human mesenchymal stem cell carries HCV receptors and essential host factors. The imHC outperformed Huh7 as a host for HCV (JFH-1) and sustained the entire HCV life cycle of pan-genotypic clinical isolates. We analyzed the alteration of host markers (i.e., hepatic markers, cellular innate immune response, and cell apoptosis) in response to HCV infection. The imHC model uncovered the underlying mechanisms governing the action of IFN-α and the activation of sofosbuvir. The insights from HCV-cell culture model hold promise for understanding disease pathogenesis and novel anti-HCV development.
Læs mere
Tjek på PubMed
8
Occult hepatitis B infection in children born to HBeAg-positive women confers a low long-term risk for HBsAg-positive infection
Infection, 12.05.2024
Tilføjet 12.05.2024
Abstract Purpose Mother-to-child transmission (MTCT) has been the main cause of chronic hepatitis B virus (HBV) infection, particularly in East Asia. Hepatitis B immunoglobulin (HBIG) and vaccination given directly after birth effectively prevents hepatitis B surface antigen (HBsAg)-positive (overt) HBV infection, but occult hepatitis B infection (OBI) may develop despite adequate prophylaxis. The aim of this study was to investigate the long-term outcome in children born to mothers with very high HBV DNA levels with special focus on children discovered in early childhood with OBI. Methods One-year and long-term outcome regarding overt and occult HBV infection were analysed in 66 children born to hepatitis B e antigen (HBeAg)-positive mothers, and were compared with one-year outcome in 69 children born to HBeAg-negative mothers. The children were born between 1998 and 2018. Results Six children born to HBeAg-positive mothers developed overt chronic HBV infection, in two cases after normal pregnancies and despite HBIG and vaccination, but never when nucleotide analogue treatment was given during pregnancy. OBI with HBV DNA detected in serum in the absence of surface antigen (HBsAg) was observed in four children at the age of 1 year. One of them was transiently HBsAg-positive at the age of 7 years. At long-term follow-up, six children had overt chronic infection, one had OBI and six had previous OBI or positive anti-HBc suggesting resolved unidentified infections. Conclusion The results indicate that children born to mothers with high HBV DNA levels have approximately 10% risk to develop OBI despite antiviral treatment, vaccination and HBIG, but that such OBI confers a minimal long-term risk for overt infection, at least in immunocompetent children.
Læs mere
Tjek på PubMed
9
Occult hepatitis B infection in children born to HBeAg-positive women confers a low long-term risk for HBsAg-positive infection
Infection, 10.05.2024
Tilføjet 10.05.2024
Abstract Purpose Mother-to-child transmission (MTCT) has been the main cause of chronic hepatitis B virus (HBV) infection, particularly in East Asia. Hepatitis B immunoglobulin (HBIG) and vaccination given directly after birth effectively prevents hepatitis B surface antigen (HBsAg)-positive (overt) HBV infection, but occult hepatitis B infection (OBI) may develop despite adequate prophylaxis. The aim of this study was to investigate the long-term outcome in children born to mothers with very high HBV DNA levels with special focus on children discovered in early childhood with OBI. Methods One-year and long-term outcome regarding overt and occult HBV infection were analysed in 66 children born to hepatitis B e antigen (HBeAg)-positive mothers, and were compared with one-year outcome in 69 children born to HBeAg-negative mothers. The children were born between 1998 and 2018. Results Six children born to HBeAg-positive mothers developed overt chronic HBV infection, in two cases after normal pregnancies and despite HBIG and vaccination, but never when nucleotide analogue treatment was given during pregnancy. OBI with HBV DNA detected in serum in the absence of surface antigen (HBsAg) was observed in four children at the age of 1 year. One of them was transiently HBsAg-positive at the age of 7 years. At long-term follow-up, six children had overt chronic infection, one had OBI and six had previous OBI or positive anti-HBc suggesting resolved unidentified infections. Conclusion The results indicate that children born to mothers with high HBV DNA levels have approximately 10% risk to develop OBI despite antiviral treatment, vaccination and HBIG, but that such OBI confers a minimal long-term risk for overt infection, at least in immunocompetent children.
Læs mere
Tjek på PubMed
10
Development and field evaluation in African and Asian countries of an HBV PCR on open polyvalent platforms to determine treatment eligibility: results from the ANRS 12327 study
Dramane KANIA, Janin NOUHIN, Karine BOLLORE, Richard NJOUOM, Thomas d'Aquin TONI, Almoustapha Issiaka MAIGA, Coumba TOURE-KANE, Nicole NGO-GIANG-HUONG, Anoumou DAGNRA, Duy Hoang Chuong LE, Françoise LUNEL-FABIANI, Joany CASTERA-GUY, Pierre-Alain RUBBO, Amandine PISONI, Jean-Christophe PLANTIER, Edouard TUAILLON
Clinical Microbiology and Infection, 10.05.2024
Tilføjet 10.05.2024
Widespread testing and treatment are essential to eliminate hepatitis B virus (HBV) infection as a public health concern. However, in resource-limited countries, access to HBV PCR is limited. In this study, we developed a quantitative HBV PCR assay on open molecular platforms and evaluate its performance in diagnosing clinically significant HBV DNA thresholds as defined by the World Health Organization (WHO) (2,000 IU/mL, 20,000 IU/mL, and 200,000 IU/mL).
Læs mere
Tjek på PubMed
11
Low HBV knowledge is associated with low HBV vaccination uptake in general adult population despite incentivization of HBV vaccination
BMC Infectious Diseases, 8.05.2024
Tilføjet 8.05.2024
Abstract Background Hepatitis B virus (HBV) vaccination in Vietnamese adults remains low and unequally distributed. We conducted a study on HBV-naïve adults living in Ho Chi Minh City, Viet Nam, to determine barriers associated with HBV vaccination uptake after removing the financial barrier by providing free coupons for HBV vaccination. Methods After being screened for HBsAg, anti-HBs, and anti-HBc, 284 HBV-naïve study participants aged 18 and over (i.e., negative for HBsAg, anti-HBs, and anti-HBc total) were provided free 3-dose HBV vaccine coupons. Next, study participants’ receipt of 1st, 2nd, and 3rd doses of HBV vaccine was documented at a pre-specified study healthcare facility, where HBV vaccines were distributed at no cost to the participants. Upon study entry, participants answered questionnaires on sociodemographics, knowledge of HBV and HBV vaccination, and related social and behavioral factors. The proportions of three doses of HBV vaccine uptake and their confidence intervals were analyzed. Associations of HBV vaccine initiation with exposures at study entry were evaluated using modified Poisson regression. Results 98.9% (281 of 284) of study participants had complete data and were included in the analysis. The proportion of participants obtaining the 1st, 2nd, and 3rd doses of HBV vaccine was 11.7% (95% Confidence Interval [95% CI] 8.0-15.5%), 10.7% (95%CI 7.1–14.3%), and 8.9% (95%CI 5.6–12.2%), respectively. On the other hand, participants were more likely to initiate the 1st dose if they had adequate knowledge of transmission (adjusted relative risk [aRR] = 2.58, 95% CI 1.12–5.92), adequate knowledge of severity (aRR = 6.75, 95%CI 3.38–13.48), and annual health-checking seeking behavior (aRR = 2.04, 95%CI 1.07–3.87). Conclusion We documented a low HBV vaccination uptake despite incentivization. However, increased vaccine initiation was associated with better HBV knowledge and annual health check-up adherence. When considering expanding HBV vaccination to the general adult population, we should appreciate that HBV knowledge is an independent predictor of vaccine uptake.
Læs mere
Tjek på PubMed
12
Correction: The association between vitamin D receptor polymorphism and phases of chronic hepatitis B infection in HBV carriers in Thailand
Prooksa Ananchuensook, Sirinporn Suksawatamnauy, Panarat Thaimai, Supachaya Sriphoosanaphan, Kessarin Thanapirom, Chinachote Teerapakpinyo, Yong Poovorawan, Piyawat Komolmit
PLoS One Infectious Diseases, 8.05.2024
Tilføjet 8.05.2024
by Prooksa Ananchuensook, Sirinporn Suksawatamnauy, Panarat Thaimai, Supachaya Sriphoosanaphan, Kessarin Thanapirom, Chinachote Teerapakpinyo, Yong Poovorawan, Piyawat Komolmit
Læs mere
Tjek på PubMed
13
People with HBV/HIV coinfection should be prioritized in HBV cure research
Clinical Infectious Diseases, 7.05.2024
Tilføjet 7.05.2024
14
Current knowledge about long-term liver outcome among HBV/HIV coinfected patients
Clinical Infectious Diseases, 7.05.2024
Tilføjet 7.05.2024
15
Do patients with nephrotic syndrome have an increased risk of osteoporosis? A nationwide population-based retrospective cohort study in Taiwan
Liao, C.-Y., Chung, C.-H., Wei, K.-Y., Tseng, M.-F., Lin, F.-H., Tsao, C.-H., Chien, W.-C., Chu, P., Wu, C.-C.
BMJ Open, 7.05.2024
Tilføjet 7.05.2024
ObjectivesTo evaluate whether nephrotic syndrome (NS) and further corticosteroid (CS) use increase the risk of osteoporosis in Asian population during the period January 2000–December 2010. DesignNationwide population-based retrospective cohort study. SettingAll healthcare facilities in Taiwan. ParticipantsA total of 28 772 individuals were enrolled. Interventions26 614 individuals with newly diagnosed NS between 2000 and 2010 were identified and included in out study. 26 614 individuals with no NS diagnosis prior to the index date were age matched as controls. Diagnosis of osteoporosis prior to the diagnosis of NS or the same index date was identified, age, sex and NS-associated comorbidities were adjusted. Primary outcome measureTo identify risk differences in developing osteoporosis among patients with a medical history of NS. ResultsAfter adjusting for covariates, osteoporosis risk was found to be 3.279 times greater in the NS cohort than in the non-NS cohort, when measured over 11 years after NS diagnosis. Stratification revealed that age older than 18 years, congestive heart failure, hyperlipidaemia, chronic kidney disease, liver cirrhosis and NS-related disease including diabetes mellitus, hepatitis B infection, hepatitis C infection, lymphoma and hypothyroidism, increased the risk of osteoporosis in the NS cohort, compared with the non-NS cohort. Additionally, osteoporosis risk was significantly higher in NS patients with CS use (adjusted HR (aHR)=3.397). The risk of osteoporosis in NS patients was positively associated with risk of hip and vertebral fracture (aHR=2.130 and 2.268, respectively). A significant association exists between NS and subsequent risk for osteoporosis. ConclusionNS patients, particularly those treated with CS, should be evaluated for subsequent risk of osteoporosis.
Læs mere
Tjek på PubMed
16
Cumulative tenofovir exposure among patients with human immunodeficiency virus/hepatitis B co-infection with differential viral suppression
Clinical Infectious Diseases, 6.05.2024
Tilføjet 6.05.2024
Abstract This case-control study explored cumulative tenofovir exposure among patients with HIV/HBV co-infection with HIV viral suppression. Among patients taking tenofovir disoproxil fumarate, median TFV-DP levels in dried blood spots were ∼3-fold lower among patients with incomplete HBV viral suppression (n=4) compared to those with complete suppression (n=5) (516 vs.1456 fmol/punch).
Læs mere
Tjek på PubMed
17
Investigating factors associated to HBV/HIV co-infected patients in antiretroviral treatment clinic, in Northeast Ethiopia
BMC Infectious Diseases, 2.05.2024
Tilføjet 2.05.2024
Abstract Background Existing research in Ethiopia has primarily focused on the individual epidemiology of HIV and HBV, often overlooking the intricate dynamics of co-infection. This study aims to address this gap by comprehensively exploring the prevalence of HBV and HIV co-infection and the associated factors influencing co-infection rates within the specific context of ART clinics. The existing study provides limited insights into the unique challenges posed by this dual infection in the Ethiopian population receiving ART. Methods An institutional-based cross-sectional study was conducted among people living with HIV aged 18 years and above attending ART clinics in northeast Ethiopia from April to May 2022. A sample size of 350(97% response rate) participants was selected by using a systematic random sampling method. Data were collected using a pre-tested interviewer-administered structured questionnaire. Data was entered into Epi Data version software and was exported to SPSS version 25 for further analysis. Descriptive statistics using Frequency, proportion, and summary measures were done. Binary logistic regressions were done to identify independent variables associated with HBV infection among HIV patients. A P-value less than 0.05 and adjusted odds ratio with a 95% confidence interval non-inclusive of one was considered statistically significant. Results The prevalence of Hepatitis B Surface Antigen (HBsAg) was identified constituting 7.14% of the study population. Females [AOR] 0.14; 95% Confidence Interval [CI] [0.041–0.478]). Participants with an educational status of only reading and writing (AOR 8.7; 95% CI [1.143–66.5]). Single individuals (AOR 2.04; 95% CI [1.346–28.6]) were associated factors. Moreover, participants with a viral load exceeding 1000 copies/ml were 6.5 times more likely to be infected with HBV compared to those with undetectable viral loads (AOR 6.53, 95% CI [1.87–22.72]). Additionally, individuals with a CD4 count ranging from 351 to 500 cells/ml were 1.2 times more likely to be infected with HBV compared to those with a CD4 count of 500 cells/ml or above (AOR 10.4, 95% CI [1.28-85]). Conclusion The prevalence of HBV infection was found to be intermediate in HIV-infected patients in the study area. Being male, marital status of single and divorced, educational level was only read and written, current viral load of > 1000 copies/ml &
Læs mere
Tjek på PubMed
18
Hepatitis C virus subtype diversity and transmission clusters characteristics among drug users in Zhuhai, South China
BMC Infectious Diseases, 30.04.2024
Tilføjet 30.04.2024
Abstract Background Hepatitis C virus (HCV) infection poses a major public health challenge globally, especially among injecting drug users. China has the world’s largest burden of HCV infections. However, little is known about the characteristics of transmission networks among drug user populations. This study aims to investigate the molecular epidemiology and transmission characteristics of HCV infections among drug users in Zhuhai, a bustling port city connecting Mainland China and its Special Administrative Regions. Methods Participants enrolled in this study were drug users incarcerated at Zhuhai’s drug rehabilitation center in 2015. Their sociodemographic and behavioral information, including gender, promiscuity, drug use method, and so forth, was collected using a standardized questionnaire. Plasmas separated from venous blood were analyzed for HCV infection through ELISA and RT-PCR methods to detect anti-HCV antibodies and HCV RNA. The 5’UTR fragment of the HCV genome was amplified and further sequenced for subtype identifications and phylogenetic analysis. The phylogenetic tree was inferred using the Maximum Likelihood method based on the Tamura-Nei model, and the transmission cluster network was constructed using Cytoscape3.8.0 software with a threshold of 0.015. Binary logistic regression models were employed to assess the factors associated with HCV infection. Results The overall prevalence of HCV infection among drug users was 44.37%, with approximately 19.69% appearing to clear the HCV virus successfully. Binary logistic regression analysis revealed that those aged over 40, engaging in injecting drug use, and being native residents were at heightened risk for HCV infection among drug user cohorts. The predominant HCV subtypes circulating among those drug users were 6a (60.26%), followed by 3b (16.7%), 3a (12.8%), 1b (6.41%) and 1a (3.85%), respectively. Molecular transmission network analysis unveiled the presence of six transmission clusters, with the largest propagation cluster consisting of 41 individuals infected with HCV subtype 6a. Furthermore, distinct transmission clusters involved eight individuals infected with subtype 3b and seven with subtype 3a were also observed. Conclusion The genetic transmission networks revealed a complex transmission pattern among drug users in Zhuhai, emphasizing the imperative for a targeted and effective intervention strategy to mitigate HCV dissemination. These insights are pivotal for shaping future national policies on HCV screening, treatment, and prevention in port cities.
Læs mere
Tjek på PubMed
19
Integrated Hepatitis C–Opioid Use Disorder Care Through Telemedicine
Journal of the American Medical Association, 29.04.2024
Tilføjet 29.04.2024
This study discusses whether facilitated telemedicine for hepatitis C treatment increases cure rates compared with standard-of-care referral to hepatitis specialists.
Læs mere
Tjek på PubMed
20
HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data
D’Antoni, Michelle L.; Andreatta, Kristen; Chang, Silvia; Cox, Stephanie; Hindman, Jason T.; Avihingsanon, Anchalee; Martin, Hal; VanderVeen, Laurie A.; Callebaut, Christian
Journal of Acquired Immune Deficiency Syndromes, 29.04.2024
Tilføjet 29.04.2024
Background: In the Phase 3 ALLIANCE study, both bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) and dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (DTG + F/TDF) achieved high rates of HIV-1 RNA suppression through Week 96 in adults with HIV-1 and hepatitis B virus (HBV) initiating treatment (NCT03547908). Here, we quantify preexisting HIV-1 resistance, evaluate its effect on HIV-1 virologic suppression, and describe postbaseline HIV-1 resistance through Week 96. Methods: Preexisting HIV-1 resistance was assessed by historical and/or screening genotyping. HIV-1 RNA suppression to
Læs mere
Tjek på PubMed
21
Hepatitis C treatment outcomes among people who inject drugs experiencing unstable versus stable housing: Systematic review and meta-analysis
Sarah Kimball, Marley Reynoso, Courtney McKnight, Don Des Jarlais
PLoS One Infectious Diseases, 27.04.2024
Tilføjet 27.04.2024
by Sarah Kimball, Marley Reynoso, Courtney McKnight, Don Des Jarlais Background The prevalence of hepatitis C virus (HCV) among people who inject drugs (PWID) is between 50–70%. Prior systematic reviews demonstrated that PWID have similar direct acting antiviral treatment outcomes compared to non-PWID; however, reviews have not examined treatment outcomes by housing status. Given the links between housing and health, identifying gaps in HCV treatment can guide future interventions. Methods We conducted a systematic review using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched six databases for articles from 2014 onward. Two reviewers conducted title/abstract screenings, full-text review, and data extraction. We extracted effect measures for treatment initiation, adherence, completion, success, and reinfection by housing status. Studies underwent quality and certainty assessments, and we performed meta-analyses as appropriate. Results Our search yielded 473 studies, eight of which met inclusion criteria. Only the treatment initiation outcome had sufficient measures for meta-analysis. Using a random-effects model, we found those with unstable housing had 0.40 (0.26, 0.62) times the odds of initiating treatment compared to those with stable housing. Other outcomes were not amenable for meta-analysis due to a limited number of studies or differing outcome definitions. Conclusions Among PWID, unstable housing appears to be a barrier to HCV treatment initiation; however, the existing data is limited for treatment initiation and the other outcomes we examined. There is a need for more informative studies to better understand HCV treatment among those with unstable housing. Specifically, future studies should better define housing status beyond a binary, static measure to capture the nuances and complexity of housing and its subsequent impact on HCV treatment. Additionally, researchers should meaningfully consider whether the outcome(s) of interest are being accurately measured for individuals experiencing unstable housing.
Læs mere
Tjek på PubMed
22
Hepatitis B virus and hepatitis C virus affect mitochondrial function through different metabolic pathways, explaining virus-specific clinical features of chronic hepatitis
Journal of Infectious Diseases, 25.04.2024
Tilføjet 25.04.2024
Abstract Background Hepatitis C virus (HCV) and hepatitis B virus (HBV) cause chronic hepatitis with important clinical differences. HCV causes hepatic steatosis and insulin resistance, while HBV confers increased risk of liver cancer. We hypothesised these differences may be due to virus-specific effects on mitochondrial function.Methods Seahorse technology was utilised to investigate effects of virus infection on mitochondrial function. Cell based assays were used to measure mitochondrial membrane potential and quantify pyruvate and lactate. Mass spectrometry was performed on mitochondria isolated from HBV expressing, HCV infected and control cells cultured with isotope-labelled amino acids, to identify proteins with different abundance. Altered expression of key mitochondrial proteins was confirmed by real time PCR and western blot.Results Reduced mitochondrial function and ATP production were observed with HCV infection and HBV expression. HCV impairs glycolysis and reduces expression of genes regulating fatty acid oxidation, promoting lipid accumulation. HBV causes lactate accumulation by increasing expression of lactate dehydrogenase A, which converts pyruvate to lactate. In HBV expressing cells there was marked enrichment of pyruvate dehydrogenase kinase, inhibiting conversion of pyruvate to acetyl-CoA and thereby reducing its availability for mitochondrial oxidative phosphorylation.Conclusions HCV and HBV impair mitochondrial function and reduce ATP production. HCV reduces acetyl-CoA availability for energy production by impairing fatty acid oxidation, causing lipid accumulation and hepatic steatosis. HBV has no effect on fatty oxidation but reduces acetyl-CoA availability by disrupting pyruvate metabolism. This promotes lactic acidosis and oxidative stress, increasing the risk of disease progression and liver cancer.
Læs mere
Tjek på PubMed
23
Noninvasive tests maintain high accuracy for advanced fibrosis in chronic hepatitis B patients with different nomenclatures of steatotic liver disease
Lin Chen, Xuemei Tao, Minghui Zeng, Yuqin Li, Jiaxin Han, Yuekui Wang, Yonggang Liu, Ruifang Shi, Rui Su, Liang Xu, Yuqiang Mi
Journal of Medical Virology, 19.04.2024
Tilføjet 19.04.2024
24
Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearance
Immunity, 22.03.2024
Tilføjet 22.03.2024
Publication date: Available online 21 March 2024 Source: Immunity Author(s): Clinton O. Ogega, Nicole E. Skinner, Marta V. Schoenle, Xander E. Wilcox, Nicole Frumento, Desiree A. Wright, Harry T. Paul, Ariadne Sinnis-Bourozikas, Kaitlyn E. Clark, Alexis Figueroa, Pamela J. Bjorkman, Stuart C. Ray, Andrew I. Flyak, Justin R. Bailey
Læs mere
Tjek på PubMed
25
Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection
Immunity, 3.01.2024
Tilføjet 3.01.2024
Publication date: Available online 2 January 2024 Source: Immunity Author(s): Nicole Frumento, Ariadne Sinnis-Bourozikas, Harry T. Paul, Georgia Stavrakis, Muhammad N. Zahid, Shuyi Wang, Stuart C. Ray, Andrew I. Flyak, George M. Shaw, Andrea L. Cox, Justin R. Bailey
Læs mere
Tjek på PubMed
26
Histomolecular characterisation of hepatitis B virus induced liver cancer
Adane Adugna;
Reviews in Medical Virology, 11.11.2023
Tilføjet 11.11.2023
Hepatitis B virus (HBV)‐associated liver cancer is the third most prevalent cancer‐related cause of death worldwide. Different studies have been done on the histomolecular analysis of HBV induced‐liver cancer including epigenetics which are dynamic molecular mechanisms to control gene expression without altering the host deoxyribonucleic acid, genomics characterise the integration of the viral genome with host genome, proteomics characterise how gene modifies and results overexpression of proteins, glycoproteomics discover different glyco‐biomarker candidates and show glycosylation in malignant hepatocytes, metabolomics characterise how HBV impairs a variety of metabolic functions during hepatocyte immortalisation, exosomes characterise immortalised liver cells in terms of their differentiation and proliferation, and autophagy plays a role in the development of hepatocarcinogenesis linked to HBV infection.
Læs mere
Tjek på PubMed
27
Virus infection participates in the occurrence and development of human diseases through monoamine oxidase
Yujie Sun; Wen Liu; Bing Luo;
Reviews in Medical Virology, 8.09.2023
Tilføjet 8.09.2023
Monoamine oxidase (MAO) is a membrane‐bound mitochondrial enzyme that maintains the steady state of neurotransmitters and other biogenic amines in biological systems through catalytic oxidation and deamination. MAO dysfunction is closely related to human neurological and psychiatric diseases and cancers. However, little is known about the relationship between MAO and viral infections in humans. This review summarises current research on how viral infections participate in the occurrence and development of human diseases through MAO. The viruses discussed in this review include hepatitis C virus, dengue virus, severe acute respiratory syndrome coronavirus 2, human immunodeficiency virus, Japanese encephalitis virus, Epstein‐Barr virus, and human papillomavirus. This review also describes the effects of MAO inhibitors such as phenelzine, clorgyline, selegiline, M‐30, and isatin on viral infectious diseases. This information will not only help us to better understand the role of MAO in the pathogenesis of viruses but will also provide new insights into the treatment and diagnosis of these viral diseases.
Læs mere
Tjek på PubMed
28
Prospects for developing an Hepatitis C virus E1E2‐based nanoparticle vaccine
Eric A. Toth; Alexander K. Andrianov; Thomas R. Fuerst;
Reviews in Medical Virology, 8.09.2023
Tilføjet 8.09.2023
Globally, more than 58 million people are chronically infected with Hepatitis C virus (HCV) with 1.5 million new infections occurring each year. An effective vaccine for HCV is therefore a major unmet medical and public health need. Since HCV rapidly accumulates mutations, vaccines must elicit the production of broadly neutralising antibodies (bnAbs) in a reproducible fashion. Decades of research have generated a number of HCV vaccine candidates. Based on the available data and research through clinical development, a vaccine antigen based on the E1E2 glycoprotein complex appears to be the best choice, but robust induction of humoral and cellular responses leading to virus neutralisation has not yet been achieved. One issue that has arisen in developing an HCV vaccine (and many other vaccines as well) is the platform used for antigen delivery. The majority of viral vaccine trials have employed subunit vaccines. However, subunit vaccines often have limited immunogenicity, as seen for HCV, and thus multiple formats must be examined in order to elicit a robust anti‐HCV immune response. Nanoparticle vaccines are gaining prominence in the field due to their ability to facilitate a controlled multivalent presentation and trafficking to lymph nodes, where they can interact with both arms of the immune system. This review discusses the potential for development of a nanoparticle‐based HCV E1E2 vaccine, with an emphasis on the potential benefits of such an approach along with the major challenges facing the incorporation of E1E2 into nanoparticulate delivery systems and how those challenges can be addressed.
Læs mere
Tjek på PubMed
29
Trends in disease burden of hepatitis B infection in Jiangsu Province, China, 1990–2021
Infectious Disease Modelling, 11.07.2023
Tilføjet 11.07.2023
Publication date: Available online 10 July 2023 Source: Infectious Disease Modelling Author(s): Kang Fang, Yingying Shi, Zeyu zhao, Yunkang Zhao, Yichao Guo, Buasivamu Abudunaibi, Huimin Qu, Qiao Liu, Guodong Kang, Zhiguo Wang, Jianli Hu, Tianmu Chen
Læs mere
Tjek på PubMed
30
Canonical fibroblast growth factors in viral infection
Giulia Lottini; Erika Plicanti; Michele Lai; Paola Quaranta; Mauro Pistello; Giulia Freer;
Reviews in Medical Virology, 10.07.2023
Tilføjet 10.07.2023
Fibroblast growth factors (FGFs) are a family of proteins that play a crucial role in the development and maintenance of various tissues in the body. There are three function‐al groups of FGFs: canonical FGFs (cFGFs), intracellularly retained FGFs, and metabolic (also called endocrine) FGFs. cFGFs are secreted and act in an autocrine/paracrine fashion to regulate differentiation during foetal development, as well as tissue repair in adults. Recent studies have also begun to unravel the role of cFGFs during viral infections, suggesting that FGF‐2 and other canonical FGFs may have an important virus‐specific role, also by the regulation of the immune response. Because dysregulation in the FGF pathways is pivotal in cancer development, FGFs are the target of many anticancer drugs. These drugs may be repurposed to treat viral infection, since dysregulation of FGF signalling has been implicated in the pathogenesis of viral infections, such as hepatitis C. Overall, the role of cFGFs during viral infection is an underrepresented area of current research. This review focuses on overviewing the effects of canonical FGFs during infection by different viruses. Many studies highlight that the effects of FGFs during viral infection may be complex and context‐dependent. While there is evidence to suggest that FGFs may have a beneficial impact on the immune response and tissue repair during viral infection, further studies are needed to fully understand the mechanisms underlying these effects and to determine in what cases FGFs could be targeted as a therapeutic approach for viral infection.
Læs mere
Tjek på PubMed
31
Diagnostic performance of hepatitis C core antigen assay to identify active infections: A systematic review and meta‐analysis
Daniel Sepúlveda‐Crespo; Ana Treviño‐Nakoura; José M. Bellón; Amanda Fernández‐Rodríguez; Pablo Ryan; Isidoro Martínez; María A. Jiménez‐Sousa; Salvador Resino;
Reviews in Medical Virology, 10.05.2023
Tilføjet 10.05.2023
Hepatitis C virus (HCV) core antigen (HCVcAg) assay is an alternative for diagnosing HCV infection in a single step. This meta‐analysis aimed to evaluate the Abbott ARCHITECT HCV Ag assay\'s diagnostic performance (validity and utility) for diagnosing active hepatitis C. PubMed, EMBASE, Scopus, Web of Science, and Cochrane Library were searched until 10 January 2023. The protocol was registered at the prospective international register of systematic reviews (PROSPERO: CRD42022337191). Abbott ARCHITECT HCV Ag assay was the test for evaluation, and nucleic acid amplification tests with a cut‐off ≤50 IU/mL were the gold standard. Statistical analysis was performed using STATA with the MIDAS module and random‐effects models. The bivariate analysis was conducted on 46 studies (18,116 samples). The pooled sensitivity was 0.96 (95% CI = 0.94–0.97), specificity 0.99 (95% CI = 0.99–1.00), positive likelihood ratio 141.81 (95% CI = 72.39–277.79), and negative likelihood ratio 0.04 (95% CI = 0.03–0.06). The area under the summary receiver operating characteristic curve was 1.00 (95% CI = 0.34–1.00). For active hepatitis C prevalence values of 0.1%–15%, the probability that a positive test was a true positive was 12%–96%, respectively, indicating that a confirmatory test should be necessary, particularly with a prevalence ≤5%. However, the probability that a negative test was a false negative was close to zero, indicating the absence of HCV infection. The validity (accuracy) of the Abbott ARCHITECT HCV Ag assay for screening active HCV infection in serum/plasma samples was excellent. Although the HCVcAg assay showed limited diagnostic utility in low prevalence settings (≤1%), it might help diagnose hepatitis C in high prevalence scenarios (≥5%).
Læs mere
Tjek på PubMed